SANOFI3,109.80

Sanofi India Limited

· Pharma & Health
₹ CrorePeersSENORESINNOVACAPPGHLMOREPENLABIOLCPSANOFICONRFDCORCHPHARMAMcap ₹7,153 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY23
31/12/2022
FY24
31/12/2023
FY25
31/12/2024
Returns
Return on Common Equity59.3948.02
Return on Assets35.1625.64
Return on Capital Employed59.5671.8550.87
Return on Invested Capital87.7857.25
Margins
EBITDA Margin30.1328.1924.38
Operating Margin28.6226.8022.56
Incremental Operating Margin-35.4337.00
Pretax Margin31.2029.6621.43
Net Income Margin21.1520.53
FCF Margin6.8821.12
Additional
Effective Tax Rate28.6927.28
Dvd Payout Ratio144.0293.06
Sustainable Growth Rate-26.143.33
Incremental Operating Margin %-35.4337.00
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY25 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.